Oporia (Lasofoxifene) - Investigational SERM for the Prevention and Treatment of Osteoporosis
Key Data:
Drug (brand / generic)
Oporia (lasofoxifene)
Company / licensee
Pfizer and Ligand Pharmaceuticals
Therapy class
SERM
Product description
Oestrogen analogue
Current indication
Prevention and treatment of osteoporosis in post-menopausal women
Market sector
Metabolic
Development status
Pre-registration US
